User:Immcarle195/CD137/Bibliography
CD137 and Cancer
[1] Review of CD137 role in regulating tumor microenvironment (TME) and its roles in therapeutic advances in cancer immunotherapy.
[2] Article that explores recent therapeutic advancements in use of anti-CD137 antibodies in tumor growth prevention and cancer immunotherapy.
- [3] More recent review on role of antibodies in cancer therapy. Though not CD137 specific, can cross-check previous article with this one for more recent information.
Alternative CD137 functions
[4] Article on CD137 (as a checkpoint regulator) functioning as a costimulatory molecule that promotes atherosclerosis and vascular inflammation.
[5] Paper that outlines how CD137 receptor functions, what it binds to, and other background information to understand CD137 involvement in disease. Its an old paper, but great to use when writing a basic overview of CD137 function before delving into recent therapeutic uses.
- [6] More recent review of role of immune checkpoints in autoimmune diseases, not CD137 specific, but can use for supplementary information alongside previous article to gain a more current perspective of CD137's role in autoimmune disease therapies.
[7] Article that reviews investigations on CD137 functioning in relation to endothelial cells and inflammatory responses in various pathogenic environments.
- ^ Makkouk, Amani; Chester, Cariad; Kohrt, Holbrook E. (2016-02-01). "Rationale for anti-CD137 cancer immunotherapy". European Journal of Cancer. 54: 112–119. doi:10.1016/j.ejca.2015.09.026. ISSN 0959-8049.
- ^ Chu, Dinh-Toi; Bac, Nguyen Duy; Nguyen, Khanh-Hoang; Tien, Nguyen Le Bao; Thanh, Vo Van; Nga, Vu Thi; Ngoc, Vo Truong Nhu; Anh Dao, Duong Thi; Hoan, Le Ngoc; Hung, Nguyen Phuc; Trung Thu, Nguyen Thi; Pham, Van-Huy; Vu, Le Nguyen; Pham, Thuy Anh Vu; B. Thimiri Govinda Raj, Deepak (2019-04-12). "An Update on Anti-CD137 Antibodies in Immunotherapies for Cancer". International Journal of Molecular Sciences. 20 (8): 1822. doi:10.3390/ijms20081822. ISSN 1422-0067.
{{cite journal}}: CS1 maint: unflagged free DOI (link) - ^ Jhajj, Harkamal S.; Lwo, Timon S.; Yao, Emily L.; Tessier, Peter M. (2023-01). "Unlocking the potential of agonist antibodies for treating cancer using antibody engineering". Trends in Molecular Medicine. 29 (1): 48–60. doi:10.1016/j.molmed.2022.09.012. ISSN 1471-4914.
{{cite journal}}: Check date values in:|date=(help) - ^ Söderström, Leif Å.; Tarnawski, Laura; Olofsson, Peder S. (2018-05). "CD137: A checkpoint regulator involved in atherosclerosis". Atherosclerosis. 272: 66–72. doi:10.1016/j.atherosclerosis.2018.03.007. ISSN 0021-9150.
{{cite journal}}: Check date values in:|date=(help) - ^ Thum, Elaine (2009). "CD137, implications in immunity and potential for therapy". Frontiers in Bioscience. Volume (14): 4173. doi:10.2741/3521. ISSN 1093-9946.
{{cite journal}}:|volume=has extra text (help) - ^ Isakov, Noah (2016). "Immune checkpoint-targeted therapy: cancer and autoimmune diseases represent two sides of the same coin". Journal of Autoimmune Disorders. 2 (2). doi:10.21767/2471-8513.100017. ISSN 2471-8513.
{{cite journal}}: CS1 maint: unflagged free DOI (link) - ^ Yuan, Wei; Xu, Chong; Li, Bo; Xia, Hao; Pan, Yingjie; Zhong, Wei; Xu, Liangjie; Chen, Rui; Wang, Bin (2021-06). "Contributions of Costimulatory Molecule CD137 in Endothelial Cells". Journal of the American Heart Association. 10 (11). doi:10.1161/jaha.120.020721. ISSN 2047-9980.
{{cite journal}}: Check date values in:|date=(help)